Soltis Investment Advisors LLC Acquires 12,096 Shares of AbbVie Inc. $ABBV

Soltis Investment Advisors LLC increased its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 55.0% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 34,077 shares of the company’s stock after purchasing an additional 12,096 shares during the period. Soltis Investment Advisors LLC’s holdings in AbbVie were worth $7,786,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Chelsea Counsel Co. bought a new stake in shares of AbbVie during the 3rd quarter worth $26,000. Westend Capital Management LLC bought a new stake in shares of AbbVie during the 4th quarter worth $29,000. Texas Capital Bancshares Inc TX bought a new stake in shares of AbbVie during the 3rd quarter worth $31,000. Legacy Wealth Managment LLC ID lifted its position in shares of AbbVie by 115.9% during the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after buying an additional 73 shares during the last quarter. Finally, WestEnd Advisors LLC lifted its position in shares of AbbVie by 160.4% during the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock worth $32,000 after buying an additional 85 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently weighed in on ABBV shares. Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday. Morgan Stanley upped their target price on AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Evercore set a $235.00 target price on AbbVie in a report on Friday. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $223.00 target price on shares of AbbVie in a report on Wednesday, January 28th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and an average target price of $253.43.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s Q1 results were supported by strong sales of Skyrizi and Rinvoq, which helped offset ongoing Humira declines and boosted the company’s 2026 guidance. Article: How Important Are Skyrizi and Rinvoq to AbbVie’s Q1 Results?
• Positive Sentiment: Analysts have turned more optimistic on AbbVie’s earnings power, with Erste Group raising FY2027 EPS estimates and the company’s long-term pipeline still viewed favorably.
• Positive Sentiment: Recent commentary highlighted AbbVie as a potentially better growth story than AstraZeneca because of its valuation, dividend profile, and pipeline strength. Article: Which Pharma Giant Offers Better Growth: AstraZeneca or AbbVie?

AbbVie Stock Down 0.1%

Shares of ABBV opened at $210.54 on Friday. AbbVie Inc. has a 12-month low of $180.25 and a 12-month high of $244.81. The business has a 50-day simple moving average of $210.27 and a two-hundred day simple moving average of $220.10. The stock has a market cap of $371.98 billion, a PE ratio of 103.71, a PEG ratio of 0.73 and a beta of 0.32.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. During the same quarter in the prior year, the firm earned $2.46 EPS. The business’s revenue for the quarter was up 12.4% compared to the same quarter last year. On average, equities research analysts expect that AbbVie Inc. will post 14.3 EPS for the current year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th were paid a $1.73 dividend. The ex-dividend date of this dividend was Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. AbbVie’s dividend payout ratio is presently 340.89%.

Insider Activity

In other news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.06% of the company’s stock.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.